Omalizumab is associated with improved asthma outcomes in children and adolescents with serum immunoglobulin E above dosing guidelines

Authors :: Claire E. Atkinson
Stephen A. Schworer
Kate Matthews
Katherine Mills
Katherine Neighbors
Allison J. Burbank
Michelle L. Hernandez
Source :: The journal of allergy and clinical immunology. In practice. 10(10)
Publication Year :: 2022

Subjects :: Adolescent
Immunology and Allergy
Humans
Anti-Asthmatic Agents
Omalizumab
Immunoglobulin E
Child
Asthma

Tools